This is not the most recent version of the article. View current version (4 NOV 2013)

Intervention Protocol

Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease

  1. Claire Arandjus2,
  2. Peter N Black1,*,
  3. Phillippa Poole3

Editorial Group: Cochrane Airways Group

Published Online: 24 JAN 2007

DOI: 10.1002/14651858.CD002309.pub2

How to Cite

Arandjus C, Black PN, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 1. Art. No.: CD002309. DOI: 10.1002/14651858.CD002309.pub2.

Author Information

  1. 1

    University of Auckland, Dept of Medicine, Auckland, New Zealand

  2. 2

    University of Auckland, Department of Medicine, Auckland, New Zealand

  3. 3

    University of Auckland, Auckland, New Zealand

*Peter N Black, Dept of Medicine, University of Auckland, Auckland Hospital, Private Bag 92024, Auckland, New Zealand. pn.black@auckland.ac.nz.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 24 JAN 2007

SEARCH

This is not the most recent version of the article. View current version (04 NOV 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the safety and efficacy of PDE4 inhibitors in the management of stable chronic obstructive pulmonary disease (COPD). Outcomes to be assessed will include lung function, quality of life, clinical outcomes, symptoms, functional exercise capacity, and adverse effects.